Company intelligence / Profile preview

Aeon Therapeutics

Irvine, California, United Stateseconomictimes.indiatimes.com ↗

Ownership: Private
Development stage: Phase 1

Overview

AEON Biopharma is advancing ABP‑450, a proprietary prabotulinumtoxinA product, through clinical development for multiple therapeutic indications. In Q4 2024, they initiated analytical studies to support a biosimilar regulatory submission under the FDA’s 351(k) pathway using BOTOX as a reference product. The goal is to access all current and future therapeutic indications of BOTOX with a single approval. No commercial products yet.

Therapeutic areas: Neurology
Modalities: Botulinum toxin complex (biologic neurotoxin)
Industry: Biotech

Drug pipeline

1 asset

ET140202

Phase 1

Indications: Hepatocellular carcinoma, Liver cancer

Beyond the preview

Go deeper on Aeon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeon Therapeutics.

Explore the full profile